First Presentation of Clinical Data On Novel Tumor Targeting Agent At Cancer Research Forum

NeoPharm, Inc.

NeoPharm, Inc. today announced that the first preliminary Phase I human clinical data on the Company's novel tumor-targeting agent - SS1(dsFv)-PE38 - was unveiled at the 38th American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Fla. from May 18-21, 2002. This early Phase I scientific and pharmacokinetic data on SS1(dsFv)-PE38, currently being studied in advanced malignancies including mesothelioma and ovarian cancer, was released at ASCO this past week. One study was included as a scientific poster presentation and another study was included as a published abstract in the 2002 ASCO Program Proceedings. Data from these ongoing clinical studies provided early evidence of patient safety, tolerability and successful dose escalation.

< Back